Stronger Life Science Patents (MichBio)

Aurora Consulting
Aurora ConsultingAurora Consulting
Stronger
Life Science Patents
This presentation is for information purposes only and does not
constitute legal advice.
ASHLEY SLOAT, Ph.D. | September 18, 2023
Ashley Sloat, Ph.D.
President & Director of Patent Strategy
an illogical, unpredictable, chaotic mess...
“
– Federal Circuit Chief Judge Paul Michel (retired)
made it difficult for inventors, businesses, and
other patent stakeholders to reliably and
predictably determine what subject matter is
patent eligible
“
– Elizabeth Prelogar, U.S. Solicitor General
innovation cannot thrive in uncertainty
“
– Kathi Vidal, USPTO Director and Under Secretary of Commerce
80%
innovation does not include patentable subject matter
Innovation doesn’t wait.
Let us be clear: investments in the biotech
industry are based entirely on patents. Without
strong patents, we cannot raise money to find
cures for disease.
“
– Hans Bishop, Founder at Altos Labs & former Head of Juno Therapeutics
Stronger Life Science Patents (MichBio)
Overview: Stronger Life Science Patents
•Eligibility and enablement
•State of the law
•Funding sources and regulatory delays
•Practical tips
•Recent legislative movements
There are seven
days in the week
and SOMEDAY isn’t
one of them.
“
Rejection & Invalidation Gates
• Section 101 – patent ineligibility or lack of utility
• Section 102 – lack of novelty
• Section 103 – the claimed invention is obvious and/or
• Section 112 – lack of adequate description
Eligibility.
What subject matters are eligible for patent protection?
Enablement.
The fundamental deal of the patent system.
Eligibility: Patentable Subject Matter
“Whoever invents or discovers any new and useful
process, machine, manufacture, or composition of
matter, or any new and useful improvement thereof,
may obtain a patent therefor, subject to the conditions
and requirements of this title.”
35 U.S.C. § 101
Eligibility: Judicial Exceptions
• Laws of nature
• Natural phenomena
• Abstract ideas
Eligibility: Judicial Exceptions
• scientific principles
• naturally occurring phenomena
• mental processes
• mathematical algorithms
Practical application of
natural phenomenon
Life Science Challenge:
The Reality of
Past 5 Years
1631 Art Unit
Molecular Bio,
Bioinformatics, Nucleic
Acids, Recombinant
DNA/RNA, Gene
Regulation
Mayo Collaborative Services v.
Prometheus Laboratories, Inc.
Unpatentable natural laws transformed into patent-eligible
applications of those laws?
Statutory
Category?
YES Judicial
Exception?
Practical
Application?
YES Significantly
More?
NO
YES
NO
YES
Eligible
NO
Subject Matter Eligibility Guidance
Process
machine
manufacture
composition of matter
Laws of nature
Natural phenomena
Abstract ideas
Not Eligible
NO
Ariosa Diagnostics, Inc. v. Sequenom, Inc.
A significant, but unpatentable, contribution to the medical field.
The solution lies in the intent
“…in applying the §101 exception, we must distinguish
between patents that claim the building blocks of
human ingenuity and those that integrate the
building blocks into something more, thereby
transforming them into a patent-eligible invention”
Alice Corp. v. CLS Bank Int’l SCOTUS opinion
The solution lies in the intent
“At some level, all inventions embody, use, reflect, rest upon,
or apply laws of nature, natural phenomena, or abstract
ideas. Thus, an invention is not rendered ineligible for patent
simply because it involves an abstract concept. Applications
of such concepts to a new and useful end … remain eligible
for patent protection.”
Alice Corp. v. CLS Bank Int’l SCOTUS opinion
Key Tips for Derisking Eligibility
• Practical applications.
• Improvement over prior art methods.
• Overcome a particular technical challenge.
• Different claim types.
Building blocks into something more
"Unless you puke, faint or die, keep going!"
– Jillian Michaels
Enablement.
The fundamental deal of the patent system.
Enablement: Adequate Description
“The specification shall contain a written description of
the invention, and of the manner and process of
making and using it, in such full, clear, concise, and
exact terms as to enable any person skilled in the art
… to make and use the same…”
35 U.S.C. § 112
Source: IPW 112 Rejections: Where They Are Found and How Applicants Handle Them
101
Patentable
Subject Matter
102
Novelty
103
Obviousness
112a
Written
Description
112b
Enablement
All
Rejection
Bases
Top Art Unit
Groups
for 112
Rejections
Source: IPW 112 Rejections: Where They Are Found and How Applicants Handle Them
Higher disclosure bar for
unpredictable arts
Life Science Challenge:
Enabling Unpredictable Arts
“the scope of enablement … varies inversely with
the degree of unpredictability of the factors involved”
Application of Joseph D. Fisher, 427 F.2d 833 (C.C.P.A. 1970)
Enablement
Mechanical arts
Physics
Chemical arts
Life Sciences
Predictability
Digital Health
The Enablement Test
“…as to enable any person skilled in the art … to make
and use the … invention.”
35 U.S.C. § 112
“…without undue experimentation”.
Minerals Separation Ltd. v. Hyde
... coupled with information known in the art ...”.
United States v. Telectronics, Inc
Genus Claim: covers a group of related
chemicals
Species Claim: covers a single compound or
narrow slice of compounds possibly without
coverage of analogs, derivatives, or
compounds in the same family
…the law has changed dramatically in the last thirty
years, to the point where it is nearly impossible to
maintain a valid genus claim. Courts almost always
hold them invalid, either at trial or on appeal.
“
Harvard Journal of Law & Technology: Death of the Genus Claim
USPTO Genus Misinformation
Disputed by Third Parties
Community reports have identified this guidance as violating the
Community Policy on Harmfully Misleading Information
United States Patent and Trademark Office
MPEP
III. WORKING EXAMPLES AND A CLAIMED GENUS
For a claimed genus, representative examples together with a statement applicable to
the genus as a whole will ordinarily be sufficient if one skilled in the art …would expect
the claimed genus could be used in that manner without undue experimentation.
Proof of enablement will be required for other members of the claimed genus only
where adequate reasons are advanced by the examiner to establish that a person
skilled in the art could not use the genus as a whole without undue experimentation.
Examples of the Genus Claim Deaths
• A nascent, unpredictable field rife with failure
can cause enablement issues
–Enzo Biochem v. Calgene (Fed. Circ. 1999)
–Claimed antisense DNA technology
• Iterative trial-and-error lead by spec can
create enablement issue
–Wyeth v. Abbott (Fed. Circ. 2010)
–Rapamycin chemicals for treatment of
restenosis
Death of the Genus Claim
• Undue Experimentation despite described
screening process allowing for straightforward ID
of working embodiments
– Idenix Pharma v. Gilead (Fed. Circ. 2019)
– 2-methyl nucleoside for treatment of HCV
• Not Enabled despite antibody science being well-
known, guidance provided, working examples,
identified specific amino acids for binding
– Amgen v. Sanofi (Supreme Court 2023)
The solution lies in the intent
A bargain between the inventor and society.
Wands Factors
1. Quantity of experimentation necessary
2. Amount of direction or guidance presented
3. Presence or absence of working examples
4. Nature of the invention
5. State of the prior art
6. Relative skill of those in the art
7. Predictability or unpredictability of the art
8. Breadth of the claims
In re Wands, 858 F.2d 731, 737 (Fed. Cir. 1988).
Key Tips for Derisking Enablement
• Provide ample direction and specificity.
• Build breadth through examples.
• Reinforce genus with species.
• Consider a narrower claim backstop.
• Disclose experimentation tips.
• File continuation applications.
• Consider alternative strategies.
Funding Sources and
Regulatory Delays
Life Science Challenges:
Gov’t grants
come with
strings
attached…
SBIR / STTR
Government Grant Gotchyas
1. Actually reduce invention to practice before using money –
otherwise Gov’t has a nonexclusive, nontransferrable,
irrevocable, paid-up license to practice the invention
throughout the world
• Even if your patent was filed before the grant….
2. If subject invention is unelected at 2 years, then gov’t
receives title of invention.
3. If hire subcontractor to perform some of the work, any subject
invention from the subcontractor cannot be assigned to your
company – subcontractor retains ownership.
Stronger Life Science Patents (MichBio)
Maximize Your Exclusivity Window
1. Patent Term Extension
2. New Drug Product Exclusivity
3. New Clinical Investigation Exclusivity
“trainers who say ‘last one’ are the
reason I have trust issues"
Reform on the horizon?
Current events and legislative solutions.
Patent Eligibility Restoration Act of 2023
• Would amend the U.S. Patent Act to clarify the
application of 35 U.S.C. Section 101 and address
uncertainty plaguing software and biotechnology
inventions
• Effectively overruling Alice and previous SCOTUS cases
such as Mayo
• Wide bipartisan and community support
Stronger Life Science Patents (MichBio)
Stronger Life
Science Patent
Resources
• This slide deck
• Blog posts on timelines and exclusivity
• Podcasts on enablement and gov’t grants
Questions or Comments?
Contact us!
ashley@aurorapatents.com
(231) 715-1001
aurorapatents.com
@AuroraPatents
Podcast @ patentlystrategic.buzzsprout.com
1 of 52

Recommended

2017 01-25 uwls-apl_biotech 112 by
2017 01-25 uwls-apl_biotech 1122017 01-25 uwls-apl_biotech 112
2017 01-25 uwls-apl_biotech 112Gary M. Myles, Ph.D.
239 views59 slides
The Case Of Incyte Genomics by
The Case Of Incyte GenomicsThe Case Of Incyte Genomics
The Case Of Incyte Genomicsjrstorella
1.2K views21 slides
Enforcement and Patentable Subject Matter: The U.S. Dilemma by
Enforcement and Patentable Subject Matter: The U.S. DilemmaEnforcement and Patentable Subject Matter: The U.S. Dilemma
Enforcement and Patentable Subject Matter: The U.S. DilemmaPatterson Thuente IP
50 views31 slides
Ethical Issues Surrounding Patenting of Human Genes and the Development of Ne... by
Ethical Issues Surrounding Patenting of Human Genes and the Development of Ne...Ethical Issues Surrounding Patenting of Human Genes and the Development of Ne...
Ethical Issues Surrounding Patenting of Human Genes and the Development of Ne...Stephen Cranwell
444 views6 slides
Biotechnology Novelty And Nonobviousness 14 Sep10 by
Biotechnology Novelty And Nonobviousness 14 Sep10Biotechnology Novelty And Nonobviousness 14 Sep10
Biotechnology Novelty And Nonobviousness 14 Sep10Gary M. Myles, Ph.D.
274 views52 slides
Gene Patenting Life By Michael Crichton Summary by
Gene Patenting Life By Michael Crichton SummaryGene Patenting Life By Michael Crichton Summary
Gene Patenting Life By Michael Crichton SummarySue Jones
2 views42 slides

More Related Content

Similar to Stronger Life Science Patents (MichBio)

THE FRONTIERS OF MONOPOLIZATION OF HUMAN GENES by
THE FRONTIERS OF MONOPOLIZATION OF HUMAN GENESTHE FRONTIERS OF MONOPOLIZATION OF HUMAN GENES
THE FRONTIERS OF MONOPOLIZATION OF HUMAN GENESSaravanan A
807 views27 slides
2020 01-28 uwls-apl_biotech_disclosure under 35_usc112 by
2020 01-28 uwls-apl_biotech_disclosure under 35_usc1122020 01-28 uwls-apl_biotech_disclosure under 35_usc112
2020 01-28 uwls-apl_biotech_disclosure under 35_usc112Gary M. Myles, Ph.D.
61 views45 slides
11 Biotechnology Patents_Subject Matter Exclusions.pptx by
11 Biotechnology Patents_Subject Matter Exclusions.pptx11 Biotechnology Patents_Subject Matter Exclusions.pptx
11 Biotechnology Patents_Subject Matter Exclusions.pptxssuserdf29f0
29 views28 slides
Patent Year In Review 2011 60 Minutes Slides by
Patent Year In Review 2011 60 Minutes SlidesPatent Year In Review 2011 60 Minutes Slides
Patent Year In Review 2011 60 Minutes Slidesemanzo7672
468 views79 slides
Biotechnology Patent Eligibility by
Biotechnology Patent EligibilityBiotechnology Patent Eligibility
Biotechnology Patent EligibilityGary M. Myles, Ph.D.
895 views97 slides
Gene patenting by
Gene patentingGene patenting
Gene patentingHina Zamir Noori
5.3K views5 slides

Similar to Stronger Life Science Patents (MichBio)(20)

THE FRONTIERS OF MONOPOLIZATION OF HUMAN GENES by Saravanan A
THE FRONTIERS OF MONOPOLIZATION OF HUMAN GENESTHE FRONTIERS OF MONOPOLIZATION OF HUMAN GENES
THE FRONTIERS OF MONOPOLIZATION OF HUMAN GENES
Saravanan A807 views
11 Biotechnology Patents_Subject Matter Exclusions.pptx by ssuserdf29f0
11 Biotechnology Patents_Subject Matter Exclusions.pptx11 Biotechnology Patents_Subject Matter Exclusions.pptx
11 Biotechnology Patents_Subject Matter Exclusions.pptx
ssuserdf29f029 views
Patent Year In Review 2011 60 Minutes Slides by emanzo7672
Patent Year In Review 2011 60 Minutes SlidesPatent Year In Review 2011 60 Minutes Slides
Patent Year In Review 2011 60 Minutes Slides
emanzo7672468 views
Predictable Results from Unpredictable Arts by Aurora Consulting
Predictable Results from Unpredictable ArtsPredictable Results from Unpredictable Arts
Predictable Results from Unpredictable Arts
Aurora Consulting467 views
Patents and intellectual property by Janet Stemwedel
Patents and intellectual propertyPatents and intellectual property
Patents and intellectual property
Janet Stemwedel657 views
SKGF_Advisory_Stem Cells-Patent Pools to the Rescue_2005 by SterneKessler
SKGF_Advisory_Stem Cells-Patent Pools to the Rescue_2005SKGF_Advisory_Stem Cells-Patent Pools to the Rescue_2005
SKGF_Advisory_Stem Cells-Patent Pools to the Rescue_2005
SterneKessler320 views
Biotech Patentable Subject Matter After Bilski by wardjohn1346
Biotech Patentable Subject Matter After BilskiBiotech Patentable Subject Matter After Bilski
Biotech Patentable Subject Matter After Bilski
wardjohn1346597 views
Non patentable inventions in india by atuljaybhaye
Non patentable inventions in indiaNon patentable inventions in india
Non patentable inventions in india
atuljaybhaye1.3K views
2002 AIPLA - Kass & Nitabach, A Roadmap For Biotechnology Patents, by Kass et... by Lawrence Kass
2002 AIPLA - Kass & Nitabach, A Roadmap For Biotechnology Patents, by Kass et...2002 AIPLA - Kass & Nitabach, A Roadmap For Biotechnology Patents, by Kass et...
2002 AIPLA - Kass & Nitabach, A Roadmap For Biotechnology Patents, by Kass et...
Lawrence Kass186 views
016 patent infringement by 456 986
016 patent infringement016 patent infringement
016 patent infringement
456 9862.3K views
Ethics and the Law: The Case of Myriad Genetics, Ethics in Patenting and Eth... by Kirby Drake
Ethics and the Law: The Case of Myriad Genetics, Ethics in Patenting and Eth...Ethics and the Law: The Case of Myriad Genetics, Ethics in Patenting and Eth...
Ethics and the Law: The Case of Myriad Genetics, Ethics in Patenting and Eth...
Kirby Drake49 views
Issues in U.S. Biotech and Pharma Patenting: Patentable Subject Matter: and t... by Patterson Thuente IP
Issues in U.S. Biotech and Pharma Patenting: Patentable Subject Matter: and t...Issues in U.S. Biotech and Pharma Patenting: Patentable Subject Matter: and t...
Issues in U.S. Biotech and Pharma Patenting: Patentable Subject Matter: and t...

More from Aurora Consulting

Patent Claims by
Patent ClaimsPatent Claims
Patent ClaimsAurora Consulting
168 views23 slides
Protect Before You Pitch (MichBio) by
Protect Before You Pitch (MichBio)Protect Before You Pitch (MichBio)
Protect Before You Pitch (MichBio)Aurora Consulting
42 views10 slides
Government Grants and Patent Rights by
Government Grants and Patent RightsGovernment Grants and Patent Rights
Government Grants and Patent RightsAurora Consulting
235 views18 slides
Open Source and Patent Rights: Collaboration with Consequences by
Open Source and Patent Rights: Collaboration with ConsequencesOpen Source and Patent Rights: Collaboration with Consequences
Open Source and Patent Rights: Collaboration with ConsequencesAurora Consulting
392 views18 slides
Amgen V. Sanofi.pdf by
Amgen V. Sanofi.pdfAmgen V. Sanofi.pdf
Amgen V. Sanofi.pdfAurora Consulting
625 views29 slides
Foreign Filing Licenses by
Foreign Filing LicensesForeign Filing Licenses
Foreign Filing LicensesAurora Consulting
469 views16 slides

More from Aurora Consulting(20)

Open Source and Patent Rights: Collaboration with Consequences by Aurora Consulting
Open Source and Patent Rights: Collaboration with ConsequencesOpen Source and Patent Rights: Collaboration with Consequences
Open Source and Patent Rights: Collaboration with Consequences
Aurora Consulting392 views
Into the Patentverse Vol. 2: AR, VR, and Virtual Infringement by Aurora Consulting
Into the Patentverse Vol. 2: AR, VR, and Virtual InfringementInto the Patentverse Vol. 2: AR, VR, and Virtual Infringement
Into the Patentverse Vol. 2: AR, VR, and Virtual Infringement
Aurora Consulting468 views
Mean Plus Function: : The Risk of Losing Your Way by Aurora Consulting
Mean Plus Function: : The Risk of Losing Your WayMean Plus Function: : The Risk of Losing Your Way
Mean Plus Function: : The Risk of Losing Your Way
Aurora Consulting538 views
American Axle: 101 Rejections of Mechanical Claims by Aurora Consulting
American Axle: 101 Rejections of Mechanical ClaimsAmerican Axle: 101 Rejections of Mechanical Claims
American Axle: 101 Rejections of Mechanical Claims
Aurora Consulting529 views
Prenuptial Patenting: Responsible Engagement with Engineering Firms by Aurora Consulting
Prenuptial Patenting: Responsible Engagement with Engineering FirmsPrenuptial Patenting: Responsible Engagement with Engineering Firms
Prenuptial Patenting: Responsible Engagement with Engineering Firms
Aurora Consulting433 views
Fortifying Life Science Patents: Eligibility and Enablement by Aurora Consulting
Fortifying Life Science Patents: Eligibility and EnablementFortifying Life Science Patents: Eligibility and Enablement
Fortifying Life Science Patents: Eligibility and Enablement
Aurora Consulting439 views
Web 3 and IP: Cryptocurrencies, Blockchain, and NFTs by Aurora Consulting
Web 3 and IP: Cryptocurrencies, Blockchain, and NFTsWeb 3 and IP: Cryptocurrencies, Blockchain, and NFTs
Web 3 and IP: Cryptocurrencies, Blockchain, and NFTs
Aurora Consulting507 views
Inventorship: Who should be listed as an inventor for a patent? by Aurora Consulting
Inventorship: Who should be listed as an inventor for a patent?Inventorship: Who should be listed as an inventor for a patent?
Inventorship: Who should be listed as an inventor for a patent?
Aurora Consulting553 views
Decrypting Software Patents: Key Insights for IP Success by Aurora Consulting
Decrypting Software Patents: Key Insights for IP SuccessDecrypting Software Patents: Key Insights for IP Success
Decrypting Software Patents: Key Insights for IP Success
Aurora Consulting677 views
Patent Searching: Sleuthing Your Way to Stronger Patents by Aurora Consulting
Patent Searching: Sleuthing Your Way to Stronger PatentsPatent Searching: Sleuthing Your Way to Stronger Patents
Patent Searching: Sleuthing Your Way to Stronger Patents
Aurora Consulting663 views
Global & U.S. Patents for Digital Health Startups by Aurora Consulting
Global & U.S. Patents for Digital Health StartupsGlobal & U.S. Patents for Digital Health Startups
Global & U.S. Patents for Digital Health Startups
Google v Oracle: The Future of Software and Fair Use by Aurora Consulting
Google v Oracle: The Future of Software and Fair UseGoogle v Oracle: The Future of Software and Fair Use
Google v Oracle: The Future of Software and Fair Use
Aurora Consulting728 views

Recently uploaded

homedoctorbook-com-book- (1).pdf by
homedoctorbook-com-book- (1).pdfhomedoctorbook-com-book- (1).pdf
homedoctorbook-com-book- (1).pdffatimasahar769
8 views14 slides
Correct handling of laboratory Rats ppt.pptx by
Correct handling of laboratory Rats ppt.pptxCorrect handling of laboratory Rats ppt.pptx
Correct handling of laboratory Rats ppt.pptxTusharChaudhary99
11 views12 slides
Peptic ulcer.pdf by
Peptic ulcer.pdfPeptic ulcer.pdf
Peptic ulcer.pdfUVAS
15 views64 slides
vitamin c.pptx by
vitamin c.pptxvitamin c.pptx
vitamin c.pptxajithkilpart
18 views13 slides
PATIENTCOUNSELLING in.pptx by
PATIENTCOUNSELLING  in.pptxPATIENTCOUNSELLING  in.pptx
PATIENTCOUNSELLING in.pptxskShashi1
29 views16 slides
Fetal and Neonatal Circulation - MBBS, Gandhi medical College Hyderabad by
Fetal and Neonatal Circulation - MBBS, Gandhi medical College Hyderabad Fetal and Neonatal Circulation - MBBS, Gandhi medical College Hyderabad
Fetal and Neonatal Circulation - MBBS, Gandhi medical College Hyderabad Swetha rani Savala
18 views16 slides

Recently uploaded(20)

Correct handling of laboratory Rats ppt.pptx by TusharChaudhary99
Correct handling of laboratory Rats ppt.pptxCorrect handling of laboratory Rats ppt.pptx
Correct handling of laboratory Rats ppt.pptx
Peptic ulcer.pdf by UVAS
Peptic ulcer.pdfPeptic ulcer.pdf
Peptic ulcer.pdf
UVAS15 views
PATIENTCOUNSELLING in.pptx by skShashi1
PATIENTCOUNSELLING  in.pptxPATIENTCOUNSELLING  in.pptx
PATIENTCOUNSELLING in.pptx
skShashi129 views
Fetal and Neonatal Circulation - MBBS, Gandhi medical College Hyderabad by Swetha rani Savala
Fetal and Neonatal Circulation - MBBS, Gandhi medical College Hyderabad Fetal and Neonatal Circulation - MBBS, Gandhi medical College Hyderabad
Fetal and Neonatal Circulation - MBBS, Gandhi medical College Hyderabad
Gastro-retentive drug delivery systems.pptx by ABG
Gastro-retentive drug delivery systems.pptxGastro-retentive drug delivery systems.pptx
Gastro-retentive drug delivery systems.pptx
ABG220 views
CMC(CHEMISTRY,MANUFACTURING AND CONTROL).pptx by JubinNath2
CMC(CHEMISTRY,MANUFACTURING AND CONTROL).pptxCMC(CHEMISTRY,MANUFACTURING AND CONTROL).pptx
CMC(CHEMISTRY,MANUFACTURING AND CONTROL).pptx
JubinNath29 views
INTRODUCTION TO PHARMACEUTICAL VALIDATION SCOPE and MERITS OF VALIDATION.pptx by ABG
INTRODUCTION TO PHARMACEUTICAL VALIDATION SCOPE and MERITS OF VALIDATION.pptxINTRODUCTION TO PHARMACEUTICAL VALIDATION SCOPE and MERITS OF VALIDATION.pptx
INTRODUCTION TO PHARMACEUTICAL VALIDATION SCOPE and MERITS OF VALIDATION.pptx
ABG115 views
The Art of naming drugs.pptx by DanaKarem1
The Art of naming drugs.pptxThe Art of naming drugs.pptx
The Art of naming drugs.pptx
DanaKarem116 views
Cholera Romy W. (3).pptx by rweth613
Cholera Romy W. (3).pptxCholera Romy W. (3).pptx
Cholera Romy W. (3).pptx
rweth61365 views
Complications & Solutions in Laparoscopic Hernia Surgery.pptx by Varunraju9
Complications & Solutions in Laparoscopic Hernia Surgery.pptxComplications & Solutions in Laparoscopic Hernia Surgery.pptx
Complications & Solutions in Laparoscopic Hernia Surgery.pptx
Varunraju9132 views
DEBATE IN CA BLADDER TMT VS CYSTECTOMY by Kanhu Charan
DEBATE IN CA BLADDER TMT VS CYSTECTOMYDEBATE IN CA BLADDER TMT VS CYSTECTOMY
DEBATE IN CA BLADDER TMT VS CYSTECTOMY
Kanhu Charan51 views

Stronger Life Science Patents (MichBio)

  • 1. Stronger Life Science Patents This presentation is for information purposes only and does not constitute legal advice. ASHLEY SLOAT, Ph.D. | September 18, 2023
  • 2. Ashley Sloat, Ph.D. President & Director of Patent Strategy
  • 3. an illogical, unpredictable, chaotic mess... “ – Federal Circuit Chief Judge Paul Michel (retired)
  • 4. made it difficult for inventors, businesses, and other patent stakeholders to reliably and predictably determine what subject matter is patent eligible “ – Elizabeth Prelogar, U.S. Solicitor General
  • 5. innovation cannot thrive in uncertainty “ – Kathi Vidal, USPTO Director and Under Secretary of Commerce
  • 6. 80% innovation does not include patentable subject matter
  • 8. Let us be clear: investments in the biotech industry are based entirely on patents. Without strong patents, we cannot raise money to find cures for disease. “ – Hans Bishop, Founder at Altos Labs & former Head of Juno Therapeutics
  • 10. Overview: Stronger Life Science Patents •Eligibility and enablement •State of the law •Funding sources and regulatory delays •Practical tips •Recent legislative movements
  • 11. There are seven days in the week and SOMEDAY isn’t one of them. “
  • 12. Rejection & Invalidation Gates • Section 101 – patent ineligibility or lack of utility • Section 102 – lack of novelty • Section 103 – the claimed invention is obvious and/or • Section 112 – lack of adequate description
  • 13. Eligibility. What subject matters are eligible for patent protection?
  • 14. Enablement. The fundamental deal of the patent system.
  • 15. Eligibility: Patentable Subject Matter “Whoever invents or discovers any new and useful process, machine, manufacture, or composition of matter, or any new and useful improvement thereof, may obtain a patent therefor, subject to the conditions and requirements of this title.” 35 U.S.C. § 101
  • 16. Eligibility: Judicial Exceptions • Laws of nature • Natural phenomena • Abstract ideas
  • 17. Eligibility: Judicial Exceptions • scientific principles • naturally occurring phenomena • mental processes • mathematical algorithms
  • 18. Practical application of natural phenomenon Life Science Challenge:
  • 19. The Reality of Past 5 Years 1631 Art Unit Molecular Bio, Bioinformatics, Nucleic Acids, Recombinant DNA/RNA, Gene Regulation
  • 20. Mayo Collaborative Services v. Prometheus Laboratories, Inc. Unpatentable natural laws transformed into patent-eligible applications of those laws?
  • 21. Statutory Category? YES Judicial Exception? Practical Application? YES Significantly More? NO YES NO YES Eligible NO Subject Matter Eligibility Guidance Process machine manufacture composition of matter Laws of nature Natural phenomena Abstract ideas Not Eligible NO
  • 22. Ariosa Diagnostics, Inc. v. Sequenom, Inc. A significant, but unpatentable, contribution to the medical field.
  • 23. The solution lies in the intent “…in applying the §101 exception, we must distinguish between patents that claim the building blocks of human ingenuity and those that integrate the building blocks into something more, thereby transforming them into a patent-eligible invention” Alice Corp. v. CLS Bank Int’l SCOTUS opinion
  • 24. The solution lies in the intent “At some level, all inventions embody, use, reflect, rest upon, or apply laws of nature, natural phenomena, or abstract ideas. Thus, an invention is not rendered ineligible for patent simply because it involves an abstract concept. Applications of such concepts to a new and useful end … remain eligible for patent protection.” Alice Corp. v. CLS Bank Int’l SCOTUS opinion
  • 25. Key Tips for Derisking Eligibility • Practical applications. • Improvement over prior art methods. • Overcome a particular technical challenge. • Different claim types. Building blocks into something more
  • 26. "Unless you puke, faint or die, keep going!" – Jillian Michaels
  • 27. Enablement. The fundamental deal of the patent system.
  • 28. Enablement: Adequate Description “The specification shall contain a written description of the invention, and of the manner and process of making and using it, in such full, clear, concise, and exact terms as to enable any person skilled in the art … to make and use the same…” 35 U.S.C. § 112
  • 29. Source: IPW 112 Rejections: Where They Are Found and How Applicants Handle Them 101 Patentable Subject Matter 102 Novelty 103 Obviousness 112a Written Description 112b Enablement All Rejection Bases
  • 30. Top Art Unit Groups for 112 Rejections Source: IPW 112 Rejections: Where They Are Found and How Applicants Handle Them
  • 31. Higher disclosure bar for unpredictable arts Life Science Challenge:
  • 32. Enabling Unpredictable Arts “the scope of enablement … varies inversely with the degree of unpredictability of the factors involved” Application of Joseph D. Fisher, 427 F.2d 833 (C.C.P.A. 1970) Enablement Mechanical arts Physics Chemical arts Life Sciences Predictability Digital Health
  • 33. The Enablement Test “…as to enable any person skilled in the art … to make and use the … invention.” 35 U.S.C. § 112 “…without undue experimentation”. Minerals Separation Ltd. v. Hyde ... coupled with information known in the art ...”. United States v. Telectronics, Inc
  • 34. Genus Claim: covers a group of related chemicals Species Claim: covers a single compound or narrow slice of compounds possibly without coverage of analogs, derivatives, or compounds in the same family
  • 35. …the law has changed dramatically in the last thirty years, to the point where it is nearly impossible to maintain a valid genus claim. Courts almost always hold them invalid, either at trial or on appeal. “ Harvard Journal of Law & Technology: Death of the Genus Claim
  • 36. USPTO Genus Misinformation Disputed by Third Parties Community reports have identified this guidance as violating the Community Policy on Harmfully Misleading Information United States Patent and Trademark Office MPEP III. WORKING EXAMPLES AND A CLAIMED GENUS For a claimed genus, representative examples together with a statement applicable to the genus as a whole will ordinarily be sufficient if one skilled in the art …would expect the claimed genus could be used in that manner without undue experimentation. Proof of enablement will be required for other members of the claimed genus only where adequate reasons are advanced by the examiner to establish that a person skilled in the art could not use the genus as a whole without undue experimentation.
  • 37. Examples of the Genus Claim Deaths • A nascent, unpredictable field rife with failure can cause enablement issues –Enzo Biochem v. Calgene (Fed. Circ. 1999) –Claimed antisense DNA technology • Iterative trial-and-error lead by spec can create enablement issue –Wyeth v. Abbott (Fed. Circ. 2010) –Rapamycin chemicals for treatment of restenosis
  • 38. Death of the Genus Claim • Undue Experimentation despite described screening process allowing for straightforward ID of working embodiments – Idenix Pharma v. Gilead (Fed. Circ. 2019) – 2-methyl nucleoside for treatment of HCV • Not Enabled despite antibody science being well- known, guidance provided, working examples, identified specific amino acids for binding – Amgen v. Sanofi (Supreme Court 2023)
  • 39. The solution lies in the intent A bargain between the inventor and society.
  • 40. Wands Factors 1. Quantity of experimentation necessary 2. Amount of direction or guidance presented 3. Presence or absence of working examples 4. Nature of the invention 5. State of the prior art 6. Relative skill of those in the art 7. Predictability or unpredictability of the art 8. Breadth of the claims In re Wands, 858 F.2d 731, 737 (Fed. Cir. 1988).
  • 41. Key Tips for Derisking Enablement • Provide ample direction and specificity. • Build breadth through examples. • Reinforce genus with species. • Consider a narrower claim backstop. • Disclose experimentation tips. • File continuation applications. • Consider alternative strategies.
  • 42. Funding Sources and Regulatory Delays Life Science Challenges:
  • 44. Government Grant Gotchyas 1. Actually reduce invention to practice before using money – otherwise Gov’t has a nonexclusive, nontransferrable, irrevocable, paid-up license to practice the invention throughout the world • Even if your patent was filed before the grant…. 2. If subject invention is unelected at 2 years, then gov’t receives title of invention. 3. If hire subcontractor to perform some of the work, any subject invention from the subcontractor cannot be assigned to your company – subcontractor retains ownership.
  • 46. Maximize Your Exclusivity Window 1. Patent Term Extension 2. New Drug Product Exclusivity 3. New Clinical Investigation Exclusivity
  • 47. “trainers who say ‘last one’ are the reason I have trust issues"
  • 48. Reform on the horizon? Current events and legislative solutions.
  • 49. Patent Eligibility Restoration Act of 2023 • Would amend the U.S. Patent Act to clarify the application of 35 U.S.C. Section 101 and address uncertainty plaguing software and biotechnology inventions • Effectively overruling Alice and previous SCOTUS cases such as Mayo • Wide bipartisan and community support
  • 51. Stronger Life Science Patent Resources • This slide deck • Blog posts on timelines and exclusivity • Podcasts on enablement and gov’t grants
  • 52. Questions or Comments? Contact us! ashley@aurorapatents.com (231) 715-1001 aurorapatents.com @AuroraPatents Podcast @ patentlystrategic.buzzsprout.com